Oxytocin Nasal Spray Boosts Compassion-Meditation Imagery in Borderline Personality Disorder Pilot

Borderline personality disorder (BPD) is marked by intense emotional instability, chronic self-criticism, and a habit of self-invalidation that often originates in childhood environments where emotions were ignored. These features make self-compassion practices especially difficult, sometimes provoking a “backdraft” of painful memories and harsh self-judgment. Compassion-based therapies aim to teach individuals to extend kindness toward themselves, which can gradually reduce emotional vulnerability and symptom severity.

Psypost

Researchers at Hospital de la Santa Creu i Sant Pau in Barcelona conducted a double-blind, randomized, placebo-controlled pilot study. Eighteen participants with formally diagnosed BPD (confirmed via the Diagnostic Interview for Borderlines, Revised) were randomly assigned to receive either a 24-IU intranasal oxytocin spray or an identical placebo. Over five weekly sessions, participants inhaled the spray, waited one hour, and then engaged in a 15-minute guided compassion meditation drawn from Contextual Compassion Training. The meditation progressed from generating loving-kindness toward a benefactor to directing the same feeling toward oneself. Participants also practiced the exercises at home daily.

Psypost

The primary outcome was the Compassion Practice Quality Scale, which rates meditation experience on a 0-100 continuum. The scale separates a mental imagery dimension (vividness and persistence of compassionate images) from a somatic dimension (bodily sensations of warmth and comfort).

Psypost

• Imagery scores: Oxytocin participants averaged ? 77, versus ? 67 for placebo.

Psypost

• Effect size: Adjusted between-group difference = 23.98 points (95 % CI 5.28–42.68), partial ?² = 0.57, indicating a large statistical effect within this sample.

Psypost

• Somatic and total scores: No meaningful differences between groups.

Psypost

All participants completed the trial without adverse side effects.

Psypost

Study lead Joaquim Soler, clinical psychologist at the hospital’s Borderline Personality Disorder Unit, emphasized gratitude toward the volunteers for undertaking a demanding meditation protocol. He clarified that the Compassion Practice Quality Scale measures the *experience* of meditation, not overall BPD symptomatology or treatment efficacy. Soler noted that the oxytocin spray was well-tolerated and that a larger randomized trial is already underway to assess broader outcome measures, quality of life, and durability of effects.

Psypost

The investigation’s small sample (n = 18) restricts statistical precision and generalizability. The cohort was overwhelmingly female, limiting insight into potential gender differences. Researchers did not evaluate overlapping personality disorders or track changes in core BPD symptoms, leaving it unclear whether improved imagery translates into clinical benefit. Additionally, the lack of improvement in somatic scores suggests that oxytocin’s effect may be confined to cognitive aspects of meditation rather than embodied experiences.

Psypost

While oxytocin enhanced the imagery dimension, overall and somatic scores remained comparable to placebo, indicating no broad enhancement of meditation quality. The study did not measure downstream outcomes such as reduced self-criticism, improved interpersonal functioning, or symptom reduction, creating a gap between observed process improvements and meaningful clinical change.

Psypost

• “Some individuals have difficulty feeling valued and exhibit a self-critical attitude, which constitutes a transdiagnostic variable that is both a source of vulnerability and a factor contributing to the persistence of mental disorders,” — Joaquim Soler, Clinical Psychologist

Psypost

• “Although intranasal oxytocin has been studied as a potential modulator of social and emotional processes, its effects in borderline personality disorder remain mixed, and few studies have examined whether it can facilitate specific processes during psychotherapy,” — Joaquim Soler

Psypost

• “In this small pilot study, participants who received intranasal oxytocin before the compassion meditation reported fewer difficulties with compassionate mental imagery than those who received placebo, after accounting for baseline scores,” — Joaquim Soler

Psypost

• “The adjusted difference between groups on the imagery dimension was 23.98 points on a 0 to 100 scale, with a 95% confidence interval ranging from 5.28 to 42.68 and a partial eta-squared of .57,” — Joaquim Soler

Psypost

• “We are preparing to report the results, which indicate that oxytocin may have beneficial effects across several relevant dimensions in borderline personality disorder, including quality of life.” — Joaquim Soler

Psypost